Operator's Information
Duk-Woo Park, MD
| Country | Korea (Republic of) |
| Specialty | Interventional Cardiologist |
- My Approach to Left Main Coronary Disease - Master\'s Skill Secret
- LM Revascularization 2022: Guidelines and Concept Change
- Long-Term Valve Durability Issues and Optimal Decision-Making: TAVR or SAVR, Mechanical or Bioprosthetic?
- Key Message from the ADAPT-TAVR Trial: What We Learned?
- Leaflet Thrombosis, Is It Clinically Relevant?
- Racial Disparities in TAVR: Similarities and Differences
- Clinical Impact of Patient-Prosthesis Mismatch After TAVR
- Pragmatic Antithrombotic Strategies According to Bleeding and Ischemic Risk
- Two Road Diverged in a Cath Lab: PCI vs CABG in Complex PCI
- How to Optimize Sapien 3 Implantation for Future Management: FCA, Bicuspid, ViV, Low risk AS
- What Is Your Choice for Adherance Hypertensive Patients with Dyslipidemia?
- Escalation and De-Escalation Strategy for CHIP-PCI Patients: The Temporal Tuning in the TAILORED-CHIP Trial
- 10-Year Final Report of PRECOMBAT Trial: Deep-Dive
- My Challenging LM PCI Case of the Year
- East-Asian Paradox for Antithrombotics: Theory, Evidence and Next Strategy
- [Master\'s Keynote Lecture] Hand Down a Secret of Left Main PCI
- Antithrombotic and Antiplatelet Choice in Complex PCI
- Integrated Use of Imaging and Physiology in Left Main PCI
- Optimal Antithrombotics After TAVR
- Current Status of TAVR in Korea and US: TP-TAVR Registry
- TAVR Will Be a Standard Treatment for All Patients with Aortic Stenosis
- Balloon-Expandable SAPIEN 3 Valve
- Bifurcation PCI: Data, Evidence, and Guidelines
- Impact of Severe Coronary Artery Calcification on PCI Outcomes
- Optimal Antithrombotics After TAVR: Ongoing Trials
- OCT Versus IVUS for Guiding PCI: Current Evidences and Ongoing OCTIVUS Trial
- 10-Year Follow-Up of MAIN-COMPARE Registry and Substudies
- Anticoagulation for TAVR: GALILEO, and Yet It Moves.
- LM Bifurcation
- East-Asian Paradox: How to Optimize P2Y12 Inhibitors for Asians?
- How To Do Successful Registry Studies?
- Bifurcation PCI 2019: What Are Novel Changes for Technique or Concept?
- Highlighting 20 years of CV Protection with Lipitor
- PCI in Post-TAVR Patients: Beyond the Barrier
- Severe Coronary Calcification: Predictors, Managing Strategy, and Outcomes
- Integrated Use of FFR and IVUS in Non-LM Bifurcation PCI
- Clinical Impact of Periprocedural Myocardial Injury After TAVR
- Optimal Antithrombotic Therapy and Ongoing Clinical Trials
- Mainstream of TAVR: Minimalist Approach
- Permanent Pacemaker and Para-valvular Leakage: How to Avoid?
- Minimalist TAVR with Edwards SAPIEN 3 Valve
- Time to Consider Different P2Y12 Strategy for Complex PCI/CHIP Patients: From OPTIMA to TAILORED-PCI Trial
- Ture Distal Left Main PCI (Medina 1,1,1 or 1,0,1) Contemporary Strategy: Provisional vs. Complex
- Metallic DES Are All Equivalent!
- TAVR in Asia: Current Challenges and Future Direction
- Comparative Outcomes of Contemporary DES in Real-World: Is There Difference?
- EBC-MAIN Like Analysis Using the Largest Real-World Left Main Database
- Valve Thrombosis, Durability and Ongoing Antithrombotic Trials for TAVR
- OPTIMA Trial: P2Y12 Dose Adjustment for East-Asian ACS Patients
- Top 10 Tips on Bifurcation PCI
- Heavily Calcified Lesion: Rotational Atherectomy and Others
- Keynote Lecture on Bifurcation PCI: Expert\'s Concept and Technique
- TAVR - Moving to Lower Risk: STS or Age Per Se?
- Standard vs. Minimalist TAVR: When and How to Change?
- [Taped Case] TAVR with Sapien
- CTEPH; Diagnosis & Treatment
- All Contemporary DES Comparison; Data from Real-World Registry (IRIS-DES)
- Trends and Outcomes of Non-LM and LM Bifurcation PCI
- How Do I Choose Sapien 3, Evolut R or Lotus in My Practice?
- Long-Term Durability Issue of TAVR; Uncertainty or Would Be OK
- Contemporary Bifurcation PCI; How Advance over Time?
- Generalizability of EXCEL and NOBLE; Comparison with IRIS-MAIN Registry
- Where to Go? - Comparative Analysis: BMS, DES vs. BVS / - The Next Step: BVS in Challenging Lesions
- Can Different DES Make a Different Outcome?
- Future in Transcatheter Heart Valve Treatment
- SYNERGY : Latest Experience from Korea
- Growing Importance of Evidence in the Management of High CV Risk Patients
- How Much Promising BRS in Real-Practice PCI?; Updated Real-World Experience and Registry Data
- Bifurcation PCI Summary; Technique or Concept?
- BRS in Left Main PCI: Clinical Data and Experience
- DES Thrombosis and Restenosis: Still Problematic in Current Real-World with Updated DES
- Effect of Statin Therapy on Cardiovascular Outcome in Dyslipidemic Patients with CKD
- BVS: They Will Replace Metallic DES?
- Comparative Outcomes of New-Generation DES: IRIS-DES
- Can BVS Replace the Metal Stent?: Current Status and Future Perspective
- Shifting the Paradigm for Lipid Management: Pathways in Achieving Improved ASCVD Outcomes
- RDN; Indications & Evidence and Future
- Use of a Point-of-Care Platelet Function Assay to Improve the Prediction of Atherothrombotic Events after DES Implantation: ASAN-VerifyNow Registry
- Long-Term Outcomes After Stenting Versus Coronary Artery Bypass Grafting for Unprotected Left Main Coronary Artery Disease: 10-Year Results of Bare-Metal Stents and 5-Year Results of Drug-Eluting Stents From the ASAN–MAIN (ASAN Medical Center–Left MAIN Revascularization) Registry
- AMC Experience of the Intervention for the Structural Heart Disease
- Early DES - What Did We Learn - Updates from the ZEST Trial
- Alternative and Next Antiplatelet Therapy Beyond ADP Blocker
- Seeing Is Believing. IVUS Is A Mandatory in All Patients!
- DES vs. CABG for Multivessel Disease: Same or Different Interpretation from Registry to RCT
- Use of VH-Findings as Surrogate Marker for Anti-Atherosclerotic Drug
- Wrapping Up Current Clinical Trials and Future Study Program
- VH AMC Clinical Experience
- Meta-Analysis of 3,900 Patients with Left Main Disease Intervention (BMS vs DES vs CABG)
- Impact of DES on Diabetes Mellitus in Long Coronary Lesion
